Low Intensity Shock Wave Therapy (LI-ESWT) for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors (LI-ESWT)
Launched by RAMBAM HEALTH CARE CAMPUS · Mar 16, 2011
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Prior prostatectomy surgery
- • ED of more than 6 months
- • Rigidity score \< 3 during PDE5i therapy
- • Non- hormonal, neurological or psychological pathology Stable heterosexual relationship for more than 3 months
- Exclusion Criteria:
- • Any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities
- • Clinically significant chronic hematological disease
- • Anti-androgens, oral or injectable androgens
- • Radiotherapy in pelvic region
About Rambam Health Care Campus
Rambam Health Care Campus is a leading medical institution located in Haifa, Israel, renowned for its comprehensive patient care, advanced research initiatives, and commitment to medical education. As a prominent clinical trial sponsor, Rambam is dedicated to advancing healthcare through innovative research and development, facilitating a wide range of clinical studies across various therapeutic areas. The campus boasts state-of-the-art facilities, a multidisciplinary team of expert researchers and clinicians, and a robust infrastructure that supports rigorous scientific inquiry and ethical standards in clinical trials. By fostering collaboration and leveraging cutting-edge technology, Rambam Health Care Campus aims to enhance treatment options and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Haifa, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials